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Despite its broad-spectrum antifungal properties, voriconazole has many side effects 
when administered systemically. The aim of this work was to develop an ethosomal 
topical delivery system for voriconazole and test its potential to enhance the 
antifungal properties and skin delivery of the drug. Voriconazole was encapsulated 
into various ethosomal preparations and the effect of phospholipid and ethanol 
concentrations on the ethosomes properties were evaluated. The ethosomes were 
evaluated for drug encapsulation efficiency, particle size and morphology and 
antifungal efficacy. Drug permeability and deposition were tested in rat abdominal 
skin. Drug encapsulation efficiency of up to 46% was obtained and it increased with 
increasing the phospholipid concentration whereas the opposite effect was observed 
for the ethanol concentration. The ethosomes had a size of 420-600 nm and negative 
zeta potential. The particle size of the ethosomes increased by increasing their ethanol 
content. The ethosomes achieved similar inhibition zones against Aspergillus flavus at 
a 2-fold lower drug concentration compared with drug solution in dimethyl sulfoxide. 
The ex vivo drug permeability through rat abdominal skin was ~6-fold higher for the 
ethosomes compared with the drug hydroalcoholic solution. Similarly, the amount of 
drug deposited in the skin was higher for the ethosomes and was dependent on the 
ethanol concentration of the ethosomes. These results confirm that voriconazole 
ethosomal preparations are promising topical delivery systems that can enhance the 
drug antifungal efficacy and improve its skin delivery.  










Voriconazole (VRC) is a broad-spectrum second-generation triazole antifungal 
agent derived from fluconazole (Maertens, 2004). This makes it active against all 
Candida species that are resistant to fluconazole (Nguyen and Yu, 1998). It is also 
effective against Fusarium species, endemic mycoses, including those that occur in 
the central nervous system, other hyaline molds, and many brown-black molds 
(Malani et al., 2015; Scott and Simpson, 2007). VRC was approved by the US food 
and drug administration in 2002 (Song et al., 2012). It is used as a first-line treatment 
for invasive aspergillosis, as well as other invasive fungal infections (Maschmeyer et 
al., 2007). Its mechanism of action involves the inhibition of cytochrome P450-
dependent 14α-lanosterol demethylation, which is a crucial step in cell membrane 
ergosterol synthesis (Johnson and Kauffman, 2003). VRC is fungistatic against 
Candida spp., whereas it is fungicidal against filamentous organisms such as 
Aspergillus species (Johnson and Kauffman, 2003; Scott and Simpson, 2007). VRC is 
also successfully used in the management of superficial fungal infections, such as 
fungal keratitis caused by Beauveria bassiana, cutaneous aspergillosis, Candida 
albicans keratitis and skin and nail fungal infections (Al-Badriyeh et al., 2009; de Sa 
et al., 2015; Klein and Blackwood, 2006; Lacroix and de Chauvin, 2008; Ogawa et 
al., 2016). 
Although VRC is available in both parenteral and well-absorbed oral 
formulations, topical drug delivery is a better choice for the treatment of cutaneous 
fungal infections to increase drug efficacy and avoid the several side effects 
associated with systemic delivery. Thus, systemic VRC causes several side effects, 
such as blurred vision, skin rashes, elevated hepatic enzyme levels, nausea and 









effects on the liver include cholestasis, hepatocytolisis, or their combination (Mihaila, 
2015). Because VRC is only available as tablets, oral suspension and injection, there 
is an unmet need for a topical drug delivery system to reduce the drug side effects and 
increase its efficacy. Careful review of the literature revealed only few studies 
reporting on the development of topical delivery systems for VRC (de Sa et al., 2015; 
El-Hadidy et al., 2012; Song et al., 2012; Song et al., 2014). Thus, liposomal VRC 
formulations were tested as a potential treatment of ocular fungal infections (de Sa et 
al., 2015). This formulation was able to deliver about 47.85±5.72  µg/cm
2
 of drug into 
porcine cornea after 30 min of permeation test. VRC was also incorporated into 
transethosomes and its skin delivery was compared to deformable liposomes, 
conventional liposomes and ethosomes (Song et al., 2012).  Transethosomes were 
better than other vesicular carriers in enhancing the skin permeation and skin 
deposition of VRC in the dermis/epidermis region.  
Ethosomes are soft, malleable vesicles composed mainly of phospholipids, 
ethanol and water (Akhtar, 2014; Bragagni et al., 2012; Zhai et al., 2015). Ethosomes 
were initially developed by Touitou et al. to overcome the limited penetration of 
liposomes into the skin (Touitou et al., 2000a). They have the potential to overcome 
some problems associated with topical drug delivery arising not only from the 
physicochemical properties of the drug but also from the biological barriers where 
they have demonstrated superior drug delivery properties over other vesicular and 
conventional dosage forms (Ainbinder and Touitou, 2005; Garg et al., 2015; Khan et 
al., 2015; Mbah et al., 2014; Pandey et al., 2015). Liposomes are usually restricted to 
the upper layers of the skin whereas ethosomes have better ability to penetrate deeper 
in the skin layers and transport the incorporated drugs more effectively due to their 









disturbance of the skin lipid bilayer organization and therefore it enhances the 
ethosomes ability to penetrate the stratum corneum (Akhtar, 2014). The size of 
ethosomes is smaller than that of liposomes prepared under the same conditions due to 
the high alcohol content (Touitou et al., 2000a).  
The aim of the present study was to prepare and characterize different VRC 
ethosomal formulations to enhance its skin delivery and improve its antifungal 
activity. The effect of different formulation variables on the vesicle properties and 
drug antifungal efficacy were evaluated.  Ex vivo skin permeation and deposition of 
VRC were tested using rat abdominal skin and were compared with those of the drug 
hydroalcoholic solution.  




; PL 90H) was purchased from 
Lipoid GmbH, D-67065 Ludwigshafen, Germany. Voriconazole (VRC) was 
purchased from Cerilliant, Round Rock, TX, USA. Dialysis membranes (Spectra/por, 
MWCO: 3.5-5 kDa, unless otherwise indicated) were purchased from Fisher 
Scientific (Rancho Dominguez, CA). Sabouraud’s dextrose agar and HPLC grade 
acetonitrile were obtained from Sigma Aldrich, St. Louis, MO, USA. Absolute 
ethanol was purchased from Adwic, EL-Naser Pharmaceutical Co., Cairo, Egypt. All 
other chemicals were of reagent grade and used as received.  
Solubility determination 
The aqueous solubility of VRC was determined by adding an excess amount 
of drug to 10 mL phosphate buffer (10 mM, pH 7.4) using a standardized shake flask 









membrane filter and the filtrate was assayed by HPLC to determine the drug 
concentration (described below). 
Preparation of ethosomes 
VRC ethosomes were prepared by the cold method as described previously 
with slight modifications (Dayan and Touitou, 2000). The composition of the 
prepared ethosomes is given in Table 1. Briefly, VRC (0.5% w/v) and phospholipids 
(3-5% w/v) were dissolved in the designated amount of absolute ethanol (35-45%, 
v/v) and stirred using a magnetic stirrer for 5 min until complete dissolution was 
obtained. Absolute alcohol was used to avoid incorporation of uncalculated amounts 
of water in the formulation. Deionized water (QS to 100%) was slowly added to the 
magnetically stirred ethanolic mixture and the preparation was stirred at 700 RPM for 
5 min at room temperature. Blank ethosomes were prepared following the same 
procedures and used as a control. The ethosomes were kept at 4 ºC for further 
analysis.   
Evaluation of the ethosomal preparations  
Determination of VRC encapsulation efficiency 
The unencapsulated drug was separated from the ethosomes by centrifugation 
at 20,000 rpm and 4 ºC for 30 min on a refrigerated centrifuge (Hettich, Germany). 
The clear supernatant was collected and aliquots were diluted 10 times by acetonitrile 
and the drug concentration was determined spectrophotometrically at absorbance 
λmax of 256 nm and using a previously constructed calibration curve. VRC 
encapsulation efficiency was calculated from the following equation:  
VRC encapsulation effeciency (weight%) =  
T−C
T
 X 100       (1)                                                      
 where T is the total amount of VRC used in the preparation, and C is the amount of 








Visualization by transmission electron microscopy  
The formation of vesicular structures, as well as the morphology of the formed 
vesicles were examined by transmission electron microscope (TEM). TEM samples 
were prepared by adding 10 μL of the ethosomal solution (Formulation F3) onto a 
Formvar-coated 400 mesh grid stabilized with evaporated carbon film. The samples 
were positively stained by adding 10 µL of aqueous uranyl acetate solution. The 
samples were allowed to dry overnight at room temperature. Photos were then 
captured using Philips CM200 electron microscope equipped with an AMT 2k x 2k 
CCD camera at an acceleration voltage of 80 kV.  
Determination of vesicle size and zeta potential  
The vesicle size, polydispersity index and zeta potential of different ethosomal 
preparations were determined using dynamic and electrophoretic light scattering using 
a Malvern Nano-ZetaSizer (Nano-ZS, Malvern Instruments, Worcestershire, UK). 
The instrument was equipped with a He-Ne laser operating at 633 nm and an 
avalanche photodiode detector. Aliquots of the ethosomal preparations were diluted 
(1:100) by the corresponding ethanol-water mixture used in their preparation. 
Measurements were performed in triplicate at room temperature 24 h after 
preparation. A cumulant analysis was applied to obtain the hydrodynamic diameter 
and polydispersity index of the ethosomes.  
In vitro antifungal activity 
Fungal strains 
Asperigillus flavus Assiut University Mycological Center (AUMC) # 1276 
was used for this study. Clotrimazole was used as an antifungal standard. The 
mycelial mat was homogenized and filtered in sterile distilled water. The colony 
forming units (CFU) were counted by hemocytometer and adjusted to 10
4










Sabouraud's dextrose agar medium (10 g/L peptone from meat, 40 g/L 
glucose, 15 g/L agar) was prepared as previously described (Moss and McQuown, 
1969). After sterilizing the medium and solidifying it in the plates, cork borer was 
used in order to make holes accepting 50 µL of the tested solution.  
Treatment 
To test the effect of drug concentration on its antifungal activity, A. flavus was 
treated with different concentrations of VRC encapsulated in ethosomes F3 (5000, 
2500, 1250, 625, 312.5, 156.25, 78.125, 38.8, 19.5, 9.8, 4.9, 2.5 µg/mL) and the 
diameter of the inhibition zones was measured. Similar drug concentrations in DMSO 
or hydroalcoholic solution (ethanol-water, 35:65, v/v) were also tested and used as 
control.  The tested sample concentrations (50 µL) were added to the holes in the  
culture plates and the plates were kept at 28
o
C ± 2 for 14 days. The inhibition zones 
were then measured. Three replicates were used for each concentration. DMSO alone 
and blank ethosomal preparations were used as negative controls.   
Ex vivo drug permeation and skin deposition studies 
Ex vivo drug skin permeation study was carried out with rat abdominal skin 
using Franz’s diffusion cell by the same method as described by Jain et al. (Jain et al., 
2007). Wistar male albino rats (6–8 weeks old), weighing 120–150 g were used for 
procuring their abdominal skin. After removing the hair, the abdominal skin was 
separated from the underlying connective tissue with scalpel. The excised skin was 
placed on aluminum foil and any adhering fat and/or subcutaneous tissue was 
carefully removed from the dermal side of the skin. The skin was checked carefully to 
ensure that the skin samples were free from any surface irregularity, such as fine holes 
or crevices in the portions that were used for transdermal permeation studies. A 









between two filter papers. Skin was used directly without storage. All animals were 
treated in accordance with the ethical guidelines approved by Assiut University.  
VRC permeation studies through rat abdominal skin were carried out using a 
receptor medium composed of pH 7.4 isotonic phosphate buffer containing 0.11% 
(w/v) formaldehyde as a preservative for the skin (Elsayed et al., 2006). Skin 
membranes were mounted between the donor and receptor compartments of diffusion 
cell with the stratum corneum side facing up. Formulations to be tested (F3, F6 and 
F9, equivalent to VRC 0.5% w/v) (0.5 mL) were applied to skin surface, which had an 
available diffusion area of 3.14 cm
2
 and covered with aluminum foil to avoid 
diffusion medium evaporation. Diffusion medium (10 mL) was maintained at 37ºC so 
that the membrane just touches the receptor medium surface. According to solubility 
data and the amount of the drug in each preparation, the receptor medium volume 
maintains sink conditions. Hydroalcoholic solution of VRC (0.5% w/v drug in 35% 
v/v ethanol/water mixture) was used as control (n = 3). The diffusion medium was 
magnetically stirred at 100 rpm. The receptor medium was kept at 37±1ºC throughout 
experiments. Half-milliliter samples of the receptor medium were removed at 
appropriate intervals (1, 2, 3, 4, 6, 8, and 24 h) and immediately replaced with fresh 
medium. VRC content of the samples was determined by HPLC. The cumulative 
amount of VRC permeated through rat skin (expressed as weight % of total VRC in 
the applied dose) was calculated and plotted as a function of time. The flux, J (μg/cm
2
 
/h) of each tested sample was calculated. 
At the end of the drug permeation studies, the skin was used to determine the 
amount of drug deposited in rat skin. For this purpose, the skin was washed with 
water and kept in methanol as a drug extraction solvent for 24 h. The methanolic 








HPLC. The cumulative amount of drug permeated through skin and the amount 
deposited in skin were plotted as a function of time. All experiments were done in 
triplicate.  
HPLC assay of VRC 
HPLC assay of VRC was done according to previously reported procedures 
with slight modification (Khetre et al., 2009). The instrument used was a Y-Lin 
Technologies 9112 series HPLC system equipped with a Synergi, 2.6 µm C18 
reversed phase column (250 x 4.6 cm). Mobile phase consisted of acetonitrile:water 
(80:20, v/v) and the flow rate was maintained at 1.0 mL/min. Injection volume was 20 
µL and VRC was detected at 256 nm with a retention time of 4.6 min. A calibration 
curve (R
2 
≥ 0.999) of VRC was prepared using standard solutions ranging in 
concentration from 0.2 to 10 µg/mL prepared immediately prior to the assay. 
Statistical analysis 
 All experiments were run in triplicate and results were expressed as mean ± 
SD. Statistical data analysis was carried out using the Graph-Pad Prism version 5 
software (USA). The data was analyzed by one-way analysis of variance (ANOVA) 
with Newman-Keuls post-hoc test. Statistical significance was predefined as p < 0.05. 
Results and discussion 
Determination of voriconazole aqueous solubility 
The solubility of VRC in phosphate buffer pH 7.4 was found to be 0.7 mg/mL. 
This is much lower than the drug solubility at pH 1.2, which is reported to be around 
3.2 mg/mL. VRC is a weakly basic drug with a pKa of 4.8, which explains its much 









Preparation and characterization of VRC ethosomal preparations 
VRC loaded ethosomes were prepared by the cold method using different 
concentrations of phospholipids, ethanol and water (Table 1) and their different drug 
delivery aspects were studied. Although VRC-loaded ethosomes were prepared 
previously by Song et al., the main focus of that study was transethosomes with 
ethosomes being used as a control. Thus, the effects of different formulation variables 
on the ethosome properties and drug delivery potential were not revealed (Song et al., 
2012). We selected the ethanol concentration in the range of 35-45%, v/v because it 
was reported that lower ethanol concentration negatively affected encapsulation 
efficiency of hydrophobic drugs while higher concentration could solubilize the 
phospholipid bilayers leading to leaky ethosomes and reduced drug loading 
(Abdulbaqi et al., 2016; Touitou et al., 2000b).   
Size and shape of the prepared ethosomes 
Particle size and shape are known to affect vesicle physical stability and 
cellular uptake (Maestrelli et al., 2009). The particle size of blank ethosomes was 
97.7±1.2 nm and it was significantly increased upon drug loading (p<0.05). Similar 
results were observed previously for paclitaxel-loaded ethosomes and were attributed 
to drug incorporation into the lipid bilayer (Paolino et al., 2012). This could lead to 
expansion of the lipid bilayer to accommodate the incorporated drug. Among the drug 
loaded formulations, the smallest size (423.67±26.64 nm) was detected for formula F2 
having lowest ethanol content (35%) and moderate phospholipid content (4%). The 
particle size of all the other formulations was within the 420-600 nm range (Table 2). 
There was a general increase in the particle size with the increase in the ethanol 
concentration in the ethosomes. For instance, the ethosome size increased from 









from 35 to 40% at a constant phospholipid concentration of 3% (Table 2). In contrast, 
increasing the phospholipid concentration while keeping the ethanol concentration 
constant had a limited influence on the ethosome particle size (Table 2). These results 
are in agreement with previous reports (Touitou et al., 2000b). The polydispersity 
index of the prepared ethosomes was ~ 0.3 for most of the formulations indicating 
fairly homogenous particle size distribution (Maestrelli et al., 2009; Mbah et al., 
2014). The morphology of the vesicles was studied by TEM (formulation F3), which 
confirmed the formation of unilamellar vesicles having homogeneous and regular 
round shape (Figure 1). The size seen in the TEM picture (about 140 nm) is smaller 
than that obtained by DLS measurements (Table 2), probably due to ethosome drying 
during preparation for TEM measurements (Gao et al., 2013). It is noteworthy that 
DLS measures size of hydrated vesicles in aqueous solution while TEM measures that 
in the dry state.   
Zeta potential of ethosomes is an important criterion that affects their stability 
and interaction with biological membranes (Touitou et al., 2000b). All the prepared 
ethosomes had a negative zeta potential ranging from ~ -10 to -36 mV (Table 2). This 
negative charge is attributed to the presence of ethanol in the ethosomes (Verma and 
Pathak, 2012). The magnitude of the ethosomes zeta potential was not affected by 
their composition. Interestingly, ethosomal preparations F3 kept at 4 °C for over six 
months did not show any signs of aggregation or fusion, a consequence of their 
negative surface charge (Bhosale and Avachat, 2013).  
VRC encapsulation efficiency 
In order to reach the maximum drug encapsulation efficiency, the ethosomes 
were prepared at different phospholipid and ethanol concentrations. Table 2 shows 








concentration, as well as the amount of ethanol used in the preparation. Thus, 
increasing the phospholipid concentration from 3 to 5% while keeping the ethanol 
content constant at 35% resulted in increasing the drug encapsulation efficiency from 
31.4±1.4 to 46.4±1.3%. This positive effect of the phospholipid concentration on the 
drug encapsulation efficiency might be attributed to the hydrophobicity of the drug, 
which facilitate hydrophobic interactions with the vesicle membranes and thus, 
enhance drug encapsulation efficiency. Similar trend was previously reported in other 
studies (Bhosale and Avachat, 2013; Fathalla et al., 2015; Maheshwari et al., 2012). 
Contrary to the phospholipid concentration effect, increasing the ethanol 
concentration in the ethosomes resulted in decreasing the drug encapsulation 
efficiency (Table 2). Thus, increasing the ethanol content from 35 to 45% while 
keeping the phospholipid content constant at 3% resulted in decreasing VRC 
encapsulation efficiency from 31.4±1.4 to 22.2±1.1%. This might be attributed to the 
increased fluidity and permeability of the vesicular membrane and increased solubility 
of the drug in ethanol leading to drug loss from the vesicles during preparation 
(Bhosale and Avachat, 2013; Maheshwari et al., 2012; Verma and Pathak, 2012).  
In vitro antifungal activity 
In order to confirm the potential of VRC ethosomes to enhance the drug 
antifungal activity and reduce the required concentration, the drug-loaded ethosomes 
(F3) were serially diluted and the minimum concentration that gave measurable 
inhibition zones against Asperigillus flavus was recorded. The formulation F3 was 
selected on the basis of high drug encapsulation efficiency (~ 46%, Table 2). The 
results were compared with similarly treated VRC solution in DMSO (0.5%, w/v) and 
VRC solution in ethanol-water mixture (35:65, v/v) (0.5% w/v). Blank ethosomes and 









but it was used here for comparison only since the limited aqueous solubility of the 
drug prevented preparation of aqueous solution. Care was taken to ensure that all the 
tested formulations have the same drug concentration (0.5% w/v). No inhibition zones 
were observed for blank ethosomes. The inhibition zone of DMSO alone was less 
than 4 mm. VRC solution in DMSO continued to be active against A. flavus up to 5 
dilutions (156.25 µg/mL) which gave an inhibition zone ~20 mm, after which no 
inhibition zone was detectable (Table 3). Interestingly, the ethosomal drug preparation 
(F3) had a similar inhibition zone against A. flavus (~20 mm) at a 2-fold lower drug 
concentration (Table 3). Thus, similar inhibition zones were detected for VRC DMSO 
solution (VRC concentration of 156.25 µg/mL) and ethosomal VRC (F3) (VRC 
concentration of 78.13 µg/mL) (Table 3, Figure 2). This is a very promising finding 
since drug antifungal activity can be achieved at much lower drug concentration. 
Lower drug concentrations decrease the incidence and severity of side effects, reduce 
economic burden of the treatment, improve patient compliance and leads to better 
therapeutic outcome (Mbah et al., 2014). However, the VRC hydroalcoholic solution 
was more active than the VRC ethosomes where similar inhibition zone was observed 
for a VRC concentration that is two times less than that in ethosomes. This might be 
attributed to better diffusion of the drug in hydroalcoholic solution since the drug in 
ethosomes will need to be released from the ethosome first to be active.  
Ex vivo drug permeability study 
The investigation of transport enhancement ability of ethosomal formulations 
(F3, F6, and F9) was measured using rat abdominal skin. These formulations were 
selected on the basis of high drug encapsulation efficiency (F3) (~ 46%, Table 2) and 
to test the effect of ethanol concentration of the drug permeability (ethanol 








cumulative amount of VRC permeated across excised rat skin as a function of time. 
The cumulative amount of drug that permeated the skin after 24 h was significantly 
higher for all the tested ethosomes compared to the drug hydroalcoholic solution 
(p<0.05). Among the tested ethosomal formulations, F3 showed significantly higher 
drug permeation (23.5±2.4%) compared to F6 (17.6±1.8%) and F9 (16±1.6%) 
(p<0.05). The difference between the drug permeability from F6 and F9 was not 
significant (p>0.05). Although the effect of ethanol as a permeation enhancer is well 
known, the higher drug permeation from the ethosomal formulations compared to the 
drug hydroalcoholic solution suggests some kind of synergistic enhancement 
mechanism between ethanol, ethosomes components and skin phospholipids (Berner 
and Liu, 1955; Touitou et al., 2000a). Ethanol has a softening effect on the 
phospholipids in ethosomes, which might make the vesicles more flexible and soft 
thus, allowing better penetration into deeper layers of the skin (Touitou et al., 2000a). 
Interaction of ethanol and ethosome phospholipids with the stratum corneum lipids 
and the subsequent modification of the intercellular lipid lamellae might also 
contribute to the enhanced permeability observed for drug-loaded ethosomes (Blume 
et al., 1993; Campani et al., 2016; Touitou et al., 2000a). This facilitates penetration 
of the drug molecules into and across the stratum corneum (Honeywell-Nguyen and 
Bouwstra, 2003; Honeywell-Nguyen et al., 2002). Similar enhancement in the drug 
permeation across the skin was previously reported for the drug-loaded ethosomes 
compared to drug hydroalcoholic solutions (Campani et al., 2016; Dayan and Touitou, 
2000; Touitou et al., 2000a). 
Further, drug flux from different ethosomes across rat abdominal skin was 
calculated and compared with that for drug hydroalcoholic solution. The transdermal 
flux of the drug from ethosomes F3 (22±2.1 µg/cm
2








significantly higher than from ethosomes F6 (16.6±1.5 µg/cm
2
/h) and ethosomes F9 
(15.2±1.6 µg/cm
2
/h) (p<0.05). Transdermal drug flux from VRC hydroalcoholic 
solution was 3.7±0.4 µg/cm
2
/h. This confirms that the drug transdermal flux from 
ethosomes was ~ 4.1-5.9-fold higher than that from hydroalcoholic solution. When 
comparing the flux from different ethosomal formulations, it is noticed that the flux 
rate increases when the concentration gradient builds up at the application site, i.e. the 
highest flux rate was obtained for the formulation having the highest drug 
encapsulation efficiency (i.e., F3, % encapsulation efficiency 46.4±1.2, Table 2). 
Stratum corneum provides the rate-limiting step in percutaneous absorption and the 
inclusion of a penetration enhancer such as ethanol might play a role in the enhanced 
skin delivery of lipophilic drugs; yet, it is not the sole factor operating (El Maghraby, 
2008; El Maghraby et al., 2015). The drug encapsulated into vesicular lipid bilayers 
might bypass the primary barrier for drug permeation, and this effect is expected to 
have a more important role in improving both skin deposition and transdermal 
permeation than the ethanol effect (Elsayed et al., 2006). This assumption is supported 
by the observation that the ethosomal formulations had a much higher VRC flux than 
the drug hydroalcoholic solution. Moreover, our results showed that the flux 
decreased with increasing ethanol concentration (F3 > F6 > F9). This might be 
attributed to the deteriorating effect of ethanol on the lipid bilayers at higher 
concentrations (Jain et al., 2007).  
Skin deposition of the drug from different formulations was also investigated 
(Figure 4). The amount of the drug deposited in skin after 24 h was significantly 
higher for ethosomes F3 (42.9±4.1%) when compared with F6 (32.3±2.8%) and F9 
(29.7±3.4%) (p<0.05). Further, the amount of drug deposited in skin from the 









tested ethosomal formulations (p<0.05). This enhanced skin deposition for the drug 
loaded into the ethosomes might be attributed to the penetration and deposition of the 
vesicles into the skin layers with the vesicles acting as a reservoir for continuous drug 
delivery (Ascenso et al., 2015; Campani et al., 2016).  
It was suggested that the high percentage of alcohol in donor compartment 
may diffuse through skin and extract deposited drug, and thus lead to decreased skin 
deposition and skin penetration with increasing the alcohol content of the ethosomes 
(F3 to F9, Table 1). Deteriorating effect of ethanol on the lipid bilayers at a higher 
concentration could also limit the absorption efficacy. Likewise, the entrapment 
efficiency of ethosomes  F6 and F9 were similar, however, the slightly higher drug 
deposition into rat abdominal skin observed with F6 may also be attributed to the 
lower percentage of ethanol (Figure 4, Table 1). 
Conclusion 
Voriconazole was efficiently loaded into ethosomal preparation with an 
encapsulation efficiency of up to ~ 46%. The encapsulation efficiency increased with 
increasing the phospholipid concentration but decreased with increasing the alcohol 
concentration. The formed ethosomes had a spherical shape and were uniform in size 
and shape. The particle size was in the nanometer range and they had a negative 
surface charge. The antifungal properties of the optimal ethosomal formulation were 
tested against A. flavus and compared with the drug DMSO solution and 
hydroalcoholic solution. The drug ethosomal solution was more active than the drug 
in DMSO but less active than the drug hydroalcoholic solution. Ex vivo permeability 
studies showed that ethosomal formulation F3 had ~6-fold enhancement in the 
amount of drug permeated across rat abdominal skin compared to the drug 









the ethosomal formulations compared to the hydroalcoholic solution, and was higher 
for the ethosomal formulations having lower ethanol content. These results confirm 
the potential of ethosomal preparations as efficient delivery system for voriconazole 
for the treatment of topical fungal infections.  
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Table 1. Composition of different voriconazole ethosomal formulations. 
Formula F1 F2 F3 F4 F5 F6 F7 F8 F9 
VRC (%, w/v) 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
Phospholipid (%, w/v) 3 4 5 3 4 5 3 4 5 
Ethanol (%, v/v) 35 35 35 40 40 40 45 45 45 




Table 2. Drug encapsulation efficiency, vesicular size and polydispersity index of 
















0 97.7±1.2 0.3±0.02 -8.5±0.35 
F1 31.4±1.4 474.34±9.1 0.29±0.05 -9.40±0.20 
F2 46.5±2.1 423.67±26.64 0.28±0.06 -18.20±0.30 
F3 46.4±1.3 459.0±19.30 0.32±0.20 -16.76±0.11 
F4 29.8±6.6 557.0±4.24 0.35±0.09 -36.65±0.92 
F5 36.8±1.3 551.0±13.1 0.36±0.07 -10.76±0.11 
F6 38.1±1.3 572.0±8.0 0.39±0.07 -17.23±0.20 
F7 22.2±1.1 561.0±14.1 0.38±0.01 -8.66±0.11 
F8 29.3±1.6 526.34±14.84 0.56±0.01 -21.43±0.30 
F9 38.7±1.3 599.67±14.46 0.42±0.06 -19.43±0.46 
a
 Percent drug encapsulation efficiency, calculated from equation (1), mean of three 
different measurements ±SD. 
b 
Vesicle size (nm), mean of three different measurements ±SD. 
c 











Table 3. Inhibition zone (mm) of different concentrations of voriconazole ethosomes 
(F3) and voriconazole solution in DMSO against A. flavus 
Concentration 
(µg/mL) 
Inhibition zone (mm) 
VRC in DMSO VRC hydroalcoholic 
solution 
Ethosomes (F3) 
5000 52.67±0.58 50.67±1.15 50.67±1.15 
2500 50.00±0.00 50.67±1.15 50.00±0.00 
1250 46.00±1.0 46.67±1.15 49.33±1.15 
625 40.33±0.58 44.00±0.00 43.33±1.15 
312.50 30.67±1.15 36.33±1.53 39.33±1.15 
156.25 20.00±0.00 31.33±1.53 34.67±1.15 
78.13 0 22.67±1.15 21.00±1.00 






















Figure 2. Inhibition zones of different concentrations of VRC ethosomal solution (F3) 
against Asperigillus flavus. (1) 78 µg/mL, (2) 156.25 µg/mL, (3) 312.5 µg/mL, (4) 
625 µg/mL, (5) 1250 µg/mL and (6) 2500 µg/mL. Culture plates were kept at 28
o
C ± 

















Figure 3. Ex vivo cumulative amount of VRC permeated through rat abdominal skin 
from ethosomes (F3 (♦), F6 (■), F9 (▲)) and from hydroalcoholic solution (x) over 
24 h.  Data are expressed as weight % of total VRC in the applied dose (mean±SD, n 























































Figure 4. Ex vivo deposition of VRC in rat abdominal skin after 24 h of application of 
ethosomes (F3, F6 and F9) and drug hydroalcoholic solution. Data are expressed as % 
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